# A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin

> **NCT01628120** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 170 (actual)

## Conditions studied

- Chronic Renal Failure Requiring Hemodialysis

## Interventions

- **BIOLOGICAL:** Epoetin Hospira

## Key facts

- **NCT ID:** NCT01628120
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05-31
- **Primary completion:** 2015-02-13
- **Final completion:** 2015-02-13
- **Target enrollment:** 170 (ACTUAL)
- **Last updated:** 2019-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01628120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01628120, "A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01628120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*